、流感持续高发，医药有望开启新一轮上涨医药生物-医药生物行业周报证券研究报告/行业周报2023年11月27日评级：增持（维持）[重Ta点bl公e_司Fi基na本nc状e]况分析师：祝嘉琦公司名称股价EPSPEPEG评级执业证书编号：S0740519040001电话：021-2031515020222023E2024E2025E20222023E2024E2025E1.46买入Email：zhujq@zts.com.cn3.22买入分析师：崔少煜迈瑞医疗281.277.929.E5311.4713.7935.5029.5024.5120.400.90买入执业证书编号：S07405220600010.730.881.0576.4264.0153.4144.531.32买入Email：cuisy@zts.com.cn恒瑞医药46.800.613.314.215.4028.0025.1519.7515.390.68买入1.311.652.1044.3335.1827.8321.941.07买入药明康德83.132.973.784.716.0621.6417.9914.4311.221.34买入0.961.241.6641.9333.4325.9819.441.5...